Figure 4.1 The use of interventional treatments by participating physicians
Figure 5.1 Percentage of physicians indicating that 20% or more of their
patients' Neuropathic Pain are associated with the diagnosis indicated
Figure 5.2 Mean percentage of physicians (Mean%p) who diagnosed NP in
patients with specific underlying conditions
Figure 5.3 Neuropathic pain in patients associated with Diabetes
Figure 5.4 Neuropathic pain in patients associated with cancer
radiotherapy or chemotherapy
Figure 5.5 Neuropathic pain in patients post general surgery
Figure 5.6 Neuropathic pain in patients with Trigeminal Neuralgia
Figure 5.7 Neuropathic pain in patients with viral infection
Figure 5.8 Neuropathic pain in patients with injury or trauma
Figure 5.9 Neuropathic pain in patients post back surgery
Figure 5.10 Neuropathic pain in patients with primary back problems
Figure 5.11 Neuropathic pain in patients with Complex Regional Pain
Syndrome (CRPS)
Figure 5.12 Neuropathic pain in patients with Multiple Sclerosis
Figure 5.13 Neuropathic pain in patients with Central Pain
Figure 5.14 Neuropathic pain in patients with Arthritis
Figure 5.15 Neuropathic pain in patients with other conditions
Table 5.1 Other diagnoses associated with Neuropathic Pain
Table 6.1 Single drug use in the treatment of Neuropathic Pain
Table 6.2 Two drugs used in the treatment of Neuropathic Pain
Table 6.3 Three drugs used in the treatment of Neuropathic Pain
Table 6.4 More than three drugs used in the treatment of Neuropathic Pain
Table 6.5 Mean drug regimens in the treatment of Neuropathic Pain
Figure 7.1 Percentage of physicians prescribing the drug classes
indicated, to more than 20% of their patients
Figure 7.2 The use of Tricyclic antidepressants in the treatment of
Neuropathic Pain
Figure 7.3 The use of Selective Serotonin Reuptake Inhibitors (SSRIs) in
the treatment of Neuropathic Pain
Figure 7.4 The use of Serotonin-Noradrenalin Reuptake Inhibitors (SNRIs)
in the treatment of Neuropathic Pain
Figure 7.5 The use of Anticonvulsants in the treatment of Neuropathic Pain
Figure 7.6 The use of Sodium Channel Blockers in the treatment of
Neuropathic Pain
Figure 7.7 The use of Opioids in the treatment of Neuropathic Pain
Figure 7.8 The use of Non-Steroidal Anti-inflammatory Drugs (NSAIDs) in
the treatment of Neuropathic Pain
Figure 7.9 The use of Cannabinoids in the treatment of Neuropathic Pain
Figure 7.10 The use of Capsaicin in the treatment of Neuropathic Pain
Figure 7.11 Average drug class prescribing practices in the treatment of
Neuropathic Pain
Figure 8.1 Most frequently prescribed tricyclic antidepressants in the
treatment of Neuropathic Pain
Figure 8.2 Second most frequently prescribed tricyclic antidepressants in
the treatment of Neuropathic Pain
Figure 8.3 Third most frequently prescribed tricyclic antidepressants in
the treatment of Neuropathic Pain
Figure 9.1 Most frequently prescribed Selective Serotonin Reuptake
Inhibitors (SSRIs) in the treatment of Neuropathic Pain
Figure 9.2 Second most frequently prescribed Selective Serotonin Reuptake
Inhibitors (SSRIs) in the treatment of Neuropathic Pain
Figure 9.3 Third most frequently prescribed Selective Serotonin Reuptake
Inhibitors (SSRIs) in the treatment of Neuropathic Pain
Figure 10.1 Most frequently prescribed Serotonin-Noradrenalin Reuptake
Inhibitors (SNRIs) in the treatment of Neuropathic Pain
Figure 10.2 Second most frequently prescribed Serotonin-Noradrenalin
Reuptake Inhibitors (SNRIs) in the treatment of Neuropathic Pain
Figure 10.3 Third most frequently prescribed Serotonin-Noradrenalin
Reuptake Inhibitors (SNRIs) in the treatment of Neuropathic Pain
Figure 11.1 Most frequently prescribed Anticonvulsants in the treatment of
Neuropathic Pain
Figure 11.2 Second most frequently prescribed Anticonvulsants in the
treatment of Neuropathic Pain
Figure 11.3 Third most frequently prescribed Anticonvulsants in the
treatment of Neuropathic Pain
Figure 12.1 Most frequently prescribed Sodium Channel Blockers in the
treatment of Neuropathic Pain
Figure 12.2 Second most frequently prescribed Sodium Channel Blockers in
the treatment of Neuropathic Pain
Figure 12.3 Third most frequently prescribed Sodium Channel Blockers in
the treatment of Neuropathic Pain
Figure 13.1 Most frequently prescribed Opioids in the treatment of
Neuropathic Pain
Figure 13.2 Second most frequently prescribed opioids in the treatment of
Neuropathic Pain
Figure 13.3 Third most frequently prescribed opioids in the treatment of
Neuropathic Pain
Figure 14.1 Most frequently prescribed Non-Steroidal Anti-Inflammatory
Drugs (NSAIDs) in the treatment of Neuropathic Pain
Figure 14.2 Second most frequently prescribed Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) in the treatment of Neuropathic Pain
Figure 14.3 Third most frequently prescribed Non-Steroidal
Anti-Inflammatory Drugs (NSAIDs) in the treatment of Neuropathic Pain
Table 15.1a Most frequently used drug class combinations for the treatment
of Neuropathic Pain
Figure 15.1 Most frequently used drug class combinations for the treatment
of Neuropathic Pain
Figure 15.2 Most frequently used numbers of drugs used in the treatment of
Neuropathic Pain.
Table 15.2a Second most frequently used drug class combinations for the
treatment of Neuropathic Pain.
Figure 15.3 Second most frequently used drug class combinations for the
treatment of Neuropathic Pain.
Figure 15.4 Second most frequently used drug numbers used in the treatment
of Neuropathic Pain.
Table 15.3a. Third most frequently used drug class combinations for the
treatment of Neuropathic Pain.
Figure 15.5 Third most frequently used drug class combinations for the
treatment of Neuropathic Pain.
Figure 15.6 Third most frequently used numbers of drugs in the treatment
of Neuropathic Pain
Figure 16.1 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Diabetes.
Figure 16.2 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with cancer radiotherapy or cancer chemotherapy
Figure 16.3 Average relief from Neuropathic Pain (% reduction) following
treatment in patients following general surgery
Figure 16.4 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Trigeminal Neuralgia
Figure 16.5 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with viral infection.
Figure 16.6 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with injury or trauma
Figure 16.7 Average relief from Neuropathic Pain (% reduction) following
treatment in patients post back surgery.
Figure 16.8 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with primary back problems
Figure 16.9 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Complex Regional Pain Syndrome (CRPS)
Figure 16.10 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Multiple Sclerosis
Figure 16.11 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Central Pain.
Figure 16.12 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with Arthritis.
Figure 16.13 Average relief from Neuropathic Pain (% reduction) following
treatment in patients with other conditions.
Figure 16.14 Comparative average relief from NP (% reduction) following
pain treatment in for all underlying conditions
Table 16.1 Comparative average relief from NP (% reduction) following pain
treatment in for all underlying conditions
Figure 17.1 The percentage of physicians who use interventional treatments
for Neuropathic Pain
Figure 17.2 The use of interventional treatments by physicians for
Neuropathic Pain (number of practitioner responses for each treatment)
Figure 17.3 The use of interventional treatments by physicians for
Neuropathic Pain (average % of physicians using treatments)
Table 17.1 The use of interventional treatments by physicians for
Neuropathic Pain (number of practitioner responses for each treatment)
Table 17.2 The use of interventional treatments by physicians for
Neuropathic Pain (average % of physicians using treatments)
Table 17.3 Other interventional treatments used by physicians for the
treatment of Neuropathic Pain
Figure 19.1 Study participants
Appendix 1. Responses of study participants to the question: What are the
major issues and challenges associated with the treatment of neuropathic pain?
Responses given by physicians to this question (which in some cases may be
brief, informal or abbreviated) are presented "as is", except in those cases
where minor grammatical or typographical corrections have been necessary for
reasons of clarity.
Appendix 2. Responses of study participants to the question: Any further
comments relating to the treatment of Neuropathic Pain? Responses physicians
to this question by physicians (which in some cases may be brief, informal or
abbreviated) are presented "as is", except in those cases where minor
grammatical or typographical corrections have been necessary for reasons of
clarity.
View Cart
